Cost-effectiveness analysis evaluates remote glycemic monitoring's impact on diabetes management, suggesting economic benefits.
Objective. To evaluate clinical and economic effectiveness of remote glycemic monitoring (RGM) in patients with type 1 and type 2 diabetes mellitus (DM) receiving non-insulin therapy in the Russian Federation. Material and methods. Cost-effectiveness analysis implied comparison of RGM with routine monitoring of adults with DM. Direct medical costs for treating DM and its complications were estimated in Markov model. Life-years saved was used as effectiveness criterion. The incremental cost-effectiveness ratio (ICER) was calculated in rubles per year of life saved for RGM compared with routine monitoring. ICER was compared with willingness-to-pay threshold equal to three times the per capita gross domestic product for 2024. The modeling time horizon was 5 years. Results. ICER for DM relative to routine practice was RUB 3.135.234.88 per life-year gained in patients with type 2 diabetes receiving non-insulin therapy, and RUB 3.146.031.73 per life-year gained in patients with type 1 diabetes that is below willingness-to-pay threshold (RUB 4.129.433.70). Conclusion. Cost-effectiveness analysis demonstrates clinical and economic effectiveness of RGM in patients with type 1 and type 2 diabetes receiving non-insulin therapy over a 5-year period.
No takes yet. Share an insight, caveat, or question.
Ryagina et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: